Wang Siyue, Hu Wenqian, Xie Yuning, Wu Hongjiao, Jia Zhenxian, Zhang Zhi, Zhang Xuemei
School of Public Health, North China University of Science and Technology, Tangshan, China.
College of Life Science, North China University of Science and Technology, Tangshan, China.
PeerJ. 2022 Jan 18;10:e12816. doi: 10.7717/peerj.12816. eCollection 2022.
Complement system plays an important role in innate immunity which involved in the changes tumor immune microenvironment by mediating the inflammatory response. This study aims to explore the relationship between complement component 7 () polymorphisms and the risk of gastric cancer (GC).
All selected SNPs of were genotyped in 471 patients and 471 controls using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Odds ratios (ORs) and 95% confidence intervals (s) were calculated by unconditional Logistic regression to analyze the relationship between each genotype and the genetic susceptibility to gastric cancer. The level of expression in GC was analyzed by Gene Expression Profiling Interactive Analysis (GEPIA) and detected by Enzyme Linked Immunosorbent Assay. Kaplan-Meier plotter were used to reveal of prognostic value in GC. We examined SNPs associated with the expression of using the GTEx database. The effect of polymorphisms on the regulatory activity of was detected by luciferase reporter assay.
Unconditional logistic regression showed that individuals with rs1376178 AA or CA genotype had a higher risk of GC with OR (95% CI) of 2.09 (1.43-3.03) and 1.88 (1.35-2.63), respectively. For rs1061429 C > A polymorphism, AA genotype was associated with the elevated risk for developing gastric cancer (OR = 2.16, 95% CI [1.37-3.38]). In stratified analysis, rs1376178 AA genotype increased the risk of GC among males (OR = 2.88, 95% CI [1.81-4.58]), but not among females (OR = 1.06, 95% CI [0.55-2.06]). Individuals carrying rs1061429 AA significantly increased the risk of gastric cancer among youngers (OR = 2.84, 95% CI [1.39-5.80]) and non-smokers (OR = 2.79, 95% CI [1.63-4.77]). was overexpressed in gastric cancer tissues and serum of cancer patients and was significantly associated with the prognosis. rs1061429 C > A variant contributed to reduced protein level of ( = 0.029), but rs1376178 didn't. Luciferase reporter assay showed that rs1376178C-containing plasmid exhibited 2.86-fold higher luciferase activity than rs1376178 A-containing plasmid ( < 0.001). We also found that rs1061429A allele contributed 1.34-fold increased luciferase activity than rs1061429C allele when co-transfected with miR-591 ( = 0.0012).
These findings highlight the role of in the development of gastric cancer.
补体系统在固有免疫中发挥重要作用,通过介导炎症反应参与肿瘤免疫微环境的改变。本研究旨在探讨补体成分7(C7)基因多态性与胃癌(GC)风险之间的关系。
使用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)对471例患者和471例对照中所有选定的C7单核苷酸多态性(SNP)进行基因分型。通过无条件逻辑回归计算比值比(OR)和95%置信区间(CI),以分析每种基因型与胃癌遗传易感性之间的关系。通过基因表达谱交互式分析(GEPIA)分析GC中C7的表达水平,并通过酶联免疫吸附测定进行检测。使用Kaplan-Meier绘图仪揭示C7在GC中的预后价值。我们使用GTEx数据库检查与C7表达相关的SNP。通过荧光素酶报告基因测定检测C7基因多态性对C7调控活性的影响。
无条件逻辑回归显示,C7 rs1376178 AA或CA基因型个体患GC的风险较高,OR(95%CI)分别为2.09(1.43 - 3.03)和1.88(1.35 - 2.63)。对于C7 rs1061429 C>A多态性,AA基因型与患胃癌风险升高相关(OR = 2.16,95%CI [1.37 - 3.38])。在分层分析中,C7 rs1376178 AA基因型增加了男性患GC的风险(OR = 2.88,95%CI [1.81 - 4.58]),但女性中未增加(OR = 1.06,95%CI [0.55 - 2.06])。携带rs1061429 AA的个体在年轻人(OR = 2.84,95%CI [1.39 - 5.80])和非吸烟者(OR = 2.79,95%CI [1.63 - 4.77])中患胃癌的风险显著增加。C7在胃癌组织和癌症患者血清中过表达,且与预后显著相关。C7 rs1061429 C>A变异导致C7蛋白水平降低(P = 0.029),但rs137,6178未导致。荧光素酶报告基因测定显示,含rs1376178C的质粒比含rs1376178A的质粒表现出高2.86倍的荧光素酶活性(P < 0.001)。我们还发现当与miR-591共转染时,rs1061429A等位基因比rs1061429C等位基因导致荧光素酶活性增加1.34倍(P = 0.0012)。
这些发现突出了C7在胃癌发生中的作用。